Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulzerasib combination therapy in advanced KRAS G12C NSCLC
NCT05504278Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fulzerasib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Innovent Biologics. Primary endpoints: Number of participants with dose limiting toxicity at 12 months, Evaluate clinical efficacy of IBI351 in combination with other therapeutic agents at 24 months and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05504278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504278.